Alexander von Gabain

Add links
Source: Wikipedia, the free encyclopedia.

Alexander von Gabain is a microbiologist, academic, founder of several biotech firms and board member of venture capital firms. He has worked at the intersection of the healthcare industry, academia and research throughout his career. He was one of the founding board members of EIT in 2008[1] and began his involvement in EIT Health in 2015.[2]

His passion for biomedical research and innovation, particularly in the fields of microbiology, immunology and vaccines, has been well-documented through numerous publications;[3] and his achievements in these fields have been well-recognised through industrial awards, academic prizes and honourable memberships.

Academic background

von Gabain obtained his PhD in

University of Heidelberg and held a post-doctorate position at Stanford University from 1979 to 1982.[4]

In the 1980s and 1990s, he was Professor at the

University of Umeå and at the Karolinska Institute in Stockholm, Sweden, as well as an advisor to pharmaceutical and biotech companies. From 1993 to 1999, he was chair of Microbiology of the University of Vienna and engaged in building the public-private partnership between the Vienna-based universities and Boehringer Ingelheim known as Vienna Biocenter.[4]

His current academic appointments include as a member of the Scientific Advisory Board of the

Max F. Perutz Laboratories, a center established by the University of Vienna and the Medical University of Vienna.[8] He also serves as Vice-President Emeritus art the Karolinska Institute in Stockholm,[4] having served as Deputy Vice-Chancellor for Innovation and Commercial Outreach between 2014 and 2017.[9]

Intercell and other innovation work

von Gabain co-founded

Vienna Stock Exchange in 2005[[10]1] and continued as Chief Scientific Officer in the Executive Board until 2009.[11] In 2011, he was appointed to the company's Supervisory Board[12] and continues to hold this position after it Intercell and Vivalis merged into the trans-European biotech enterprise, Valneva, listed on Euronext Paris since 2013[13] and on Nasdaq since 2021.[14] Valneva
has today two global vaccines on the market, more than 600 employees and three major vaccines in late clinical development.

Additionally, he has supported other biotech enterprises and related VC firms in various functions. His entrepreneurial and scientific knowledge in the innovation arena has been highly sought after by organisations fostering entrepreneurial innovation. Between 2007 and 2019, he was Chair of INiTS, the technology seed fund and incubator of the University of Vienna and the Technical University of Vienna,[15] initiating more than 300 start-ups and ranking amongst the top ten of university incubators globally.[16] He is currently a member of the Supervisory Board of Eveliqure- an innovative biotech company developing novel vaccines for the prevention of diarrhoeal disease,[17] a member of the Supervisory Board of Biocopy- whose patented biomolecule copier is used for the production and replication of all kinds of different microarrays.[18]

EIT and EIT Health

In 2008, he was appointed as a founding member of the Governing Board of the European Institute of Innovation and Technology (EIT)[1] and in 2011 was elected to become its Chairman for a period ending in 2014.[4][19] During this time, the first three of EIT's Knowledge and Innovation Communities (KICs) were established and EIT evolved into a multi-billion dollar organisation.

In 2015, he joined the Supervisory Board of EIT Health[20] - an innovation consortium with more than 150 leading organisations and institutions from the European healthcare space.[4] In 2017, he was appointed Chair of the organisations Supervisory Board,[21] a position he held until 2021.[22]

References

  1. ^ a b "Official appointment of the EIT Governing Board: the European Institute of Innovation and Technology set for an Autumn launch in Budapest". Archived from the original on 2020-10-25.
  2. ^ "Science Business". Archived from the original on 2017-10-19.
  3. ^ "von Gabain a - Search Results - PubMed". PubMed. Retrieved 2021-12-20.
  4. ^ a b c d e "CV from EIT Health" (PDF). Archived (PDF) from the original on 2020-12-31.
  5. ^ "Scientific Advisory Board of Paul-Ehrlich Institute" (PDF). Archived (PDF) from the original on 2021-04-20.
  6. ^ "Board of Trustees of IST Austria". Archived from the original on 2020-05-04.
  7. ^ "International Fellows of the Royal Swedish Academy of Engineering Sciences". Archived from the original on 2020-09-25.
  8. ^ "RsearchGate.net Profile". Archived from the original on 2021-12-20.
  9. ^ "Karolinska Institutet News Article". Archived from the original on 2021-12-20.
  10. ^ "Life Science Austria - Vienna Region's Newsletter" (PDF). January 2005. Archived (PDF) from the original on 2019-10-15.
  11. ^ "Intercell Geschäftsbericht 2009v". April 2010. Archived from the original on 2010-05-06.
  12. ^ "Intercell Press Release". 5 May 2011. Archived from the original on 2020-08-15.
  13. ^ "Valneva Press Information" (PDF). Archived (PDF) from the original on 2021-12-20.
  14. ^ "Valneva Press Release". Archived from the original on 2021-05-06.
  15. ^ "INiTS Universitäres Gründerservice Wien congratulates Sabine Seidler, Heinz Engl and Alexander von Gabain". Archived from the original on 2021-12-20.
  16. ^ "Wiener INiTS in den Top 10 der Uni-Inkubatoren". 27 November 2015. Archived from the original on 2021-12-20.
  17. ^ "Eveliqure Board". Archived from the original on 2020-08-07.
  18. ^ "BioCopy AG". Archived from the original on 2020-08-15.
  19. ^ "Alexander von Gabain starts as Chairman of the EIT Governing Board". 14 September 2011. Archived from the original on 2019-06-15.
  20. ^ "Home". eithealth.eu.
  21. ^ "EIT Health appoints Alexander von Gabain Supervisory Board Chairman". Archived from the original on 2017-10-19.
  22. ^ "EIT Health announces new Supervisory Board". Archived from the original on 2021-09-28.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Alexander_von_Gabain&oldid=1133261097"